Last reviewed · How we verify
Four-Weekly TC Consolidation Chemotherapy
Four-Weekly TC Consolidation Chemotherapy is a Chemotherapy combination (taxane + platinum agent) Small molecule drug developed by Jiangsu Cancer Institute & Hospital. It is currently in Phase 3 development for Consolidation therapy in advanced or metastatic cancer (specific indication not specified in available data).
Four-weekly TC consolidation chemotherapy combines paclitaxel and carboplatin administered on an extended schedule to eliminate residual cancer cells after initial treatment.
Four-weekly TC consolidation chemotherapy combines paclitaxel and carboplatin administered on an extended schedule to eliminate residual cancer cells after initial treatment. Used for Consolidation therapy in advanced or metastatic cancer (specific indication not specified in available data).
At a glance
| Generic name | Four-Weekly TC Consolidation Chemotherapy |
|---|---|
| Sponsor | Jiangsu Cancer Institute & Hospital |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TC (paclitaxel/carboplatin) is a standard chemotherapy doublet where paclitaxel stabilizes microtubules to disrupt cell division and carboplatin cross-links DNA to induce apoptosis. The four-weekly consolidation schedule delivers these agents at extended intervals following initial therapy to target remaining malignant cells while allowing recovery between cycles.
Approved indications
- Consolidation therapy in advanced or metastatic cancer (specific indication not specified in available data)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy
- Nausea/vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Four-Weekly TC Consolidation Chemotherapy CI brief — competitive landscape report
- Four-Weekly TC Consolidation Chemotherapy updates RSS · CI watch RSS
- Jiangsu Cancer Institute & Hospital portfolio CI
Frequently asked questions about Four-Weekly TC Consolidation Chemotherapy
What is Four-Weekly TC Consolidation Chemotherapy?
How does Four-Weekly TC Consolidation Chemotherapy work?
What is Four-Weekly TC Consolidation Chemotherapy used for?
Who makes Four-Weekly TC Consolidation Chemotherapy?
What drug class is Four-Weekly TC Consolidation Chemotherapy in?
What development phase is Four-Weekly TC Consolidation Chemotherapy in?
What are the side effects of Four-Weekly TC Consolidation Chemotherapy?
Related
- Drug class: All Chemotherapy combination (taxane + platinum agent) drugs
- Manufacturer: Jiangsu Cancer Institute & Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Consolidation therapy in advanced or metastatic cancer (specific indication not specified in available data)
- Compare: Four-Weekly TC Consolidation Chemotherapy vs similar drugs
- Pricing: Four-Weekly TC Consolidation Chemotherapy cost, discount & access